FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283381098> ?p ?o ?g. }

• W4283381098 endingPage "1802" @default.
• W4283381098 startingPage "1801" @default.
• W4283381098 abstract "Background: 5-azacitidine (AZA) is the frontline standard of care in HR MDS, defined as intermediate-, high-, or very-high-risk MDS per the Revised International Prognostic Scoring System (IPSS-R). Real-world studies reporting on the effectiveness of AZA were often limited by sample size or lacked standardized response assessments based on International Working Group (IWG) criteria. Aims: To assess the effectiveness of frontline AZA in treatment-naive adult patients with HR MDS in a real-world setting. Methods: This retrospective cohort study examined outcomes in treatment-naive adult patients with HR MDS who started frontline AZA between 1 Jan 2014 and 1 Jan 2020, identified from the US Oncology Network Electronic Health Record (EHR) database. Key exclusionary criteria were receipt of any prior antileukemic therapy, stem cell transplant within 6 months of AZA initiation, active second malignancies, participation in a clinical trial during the study period, or off-label use of AZA regimens. Data were abstracted by targeted chart review into an electronic case report form from AZA initiation until the earlier of 1 Jan 2021 or death. Effectiveness of AZA was assessed using IWG 2006. Real-world equivalent (based on EHR only) of these endpoints were also derived. All responses were adjudicated by an independent hematologist. Results: Overall, 932 patients with HR MDS were identified, of whom 382 were eligible. Study population was majority male (243 [63.6%]), had a median age of 74 years, and consisted of IPSS-R intermediate-, high-, and very-high-risk categories in 164 (42.9%), 150 (39.3%), and 68 patients (17.8%), respectively. There were 101 patients (26.4%) with poor cytogenetic risk and 46 (12%) with TP53 mutation. Overall median duration on the study was 12.9 months, and median duration on AZA was 4.9 months; reasons for AZA discontinuation were: disease progression, 135 (35.3%); adverse event, 55 (14.4%); death, 41 (10.7%); and palliation, 36 (9.4%). Based on IWG 2006, 30 patients (7.9%) achieved complete remission (CR), with 240 (62.8%) achieving an objective response (OR; defined as CR, marrow CR [mCR], partial remission [PR], or hematologic improvement [HI]). IWG 2006–based median (95% CI) duration of OR, progression-free survival, time to next treatment, and overall survival (OS) were 9.5 (7.7-10.6), 9.1 (8.0-10.8), 11.5 (9.5-12.6), and 17.9 (15.5-21.7) months, respectively. Presence of poor cytogenetic risk appeared to reduce OS (Table). Estimates for response categories based on IWG 2006 differed from those based on EHR, but OR rates (ORRs) were similar (Table). Table - All patientsIWG 2006(n=382) All patientsEHR based(n=382) Poor cytogenetic riskIWG 2006(n=101) CR, n (%) 30 (7.9) 14 (3.7) 8 (7.9) 95% CI 5.4-11.0 2.0-6.1 3.5-15.0 mCR, n (%) 31 (8.1) 13 (3.4) 10 (9.9) PR, n (%) 0 120 (31.4) 0 HI, n (%) 179 (46.9) 112 (29.3) 43 (42.6) ORR, n (%) 240 (62.8) 259 (67.8) 61 (60.4) 95% CI 57.8-67.7 62.9-72.5 50.2-70.0 Duration of CR, median, months 12.0 13.5 15.6 95% CI 7.7-15.6 4.5-21.5 1.7-39.2 OS, median, months 17.9 12.8 95% CI 15.5-21.7 10.3-15.5 Summary/Conclusion: In this, one of the largest real-world HR MDS cohorts, CR and OS with AZA in treatment-naive patients were limited. Novel agents are urgently needed to improve the CR and survival rates in these patients." @default.
• W4283381098 created "2022-06-25" @default.
• W4283381098 creator A5005591514 @default.
• W4283381098 creator A5029369362 @default.
• W4283381098 creator A5048816219 @default.
• W4283381098 creator A5050903040 @default.
• W4283381098 creator A5054408146 @default.
• W4283381098 creator A5056037943 @default.
• W4283381098 creator A5059075541 @default.
• W4283381098 creator A5070528077 @default.
• W4283381098 creator A5074025538 @default.
• W4283381098 creator A5080556076 @default.
• W4283381098 date "2022-06-01" @default.
• W4283381098 modified "2023-09-26" @default.
• W4283381098 title "PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS" @default.
• W4283381098 doi "https://doi.org/10.1097/01.hs9.0000850540.71502.0d" @default.
• W4283381098 hasPublicationYear "2022" @default.
• W4283381098 type Work @default.
• W4283381098 citedByCount "0" @default.
• W4283381098 crossrefType "journal-article" @default.
• W4283381098 hasAuthorship W4283381098A5005591514 @default.
• W4283381098 hasAuthorship W4283381098A5029369362 @default.
• W4283381098 hasAuthorship W4283381098A5048816219 @default.
• W4283381098 hasAuthorship W4283381098A5050903040 @default.
• W4283381098 hasAuthorship W4283381098A5054408146 @default.
• W4283381098 hasAuthorship W4283381098A5056037943 @default.
• W4283381098 hasAuthorship W4283381098A5059075541 @default.
• W4283381098 hasAuthorship W4283381098A5070528077 @default.
• W4283381098 hasAuthorship W4283381098A5074025538 @default.
• W4283381098 hasAuthorship W4283381098A5080556076 @default.
• W4283381098 hasBestOaLocation W42833810981 @default.
• W4283381098 hasConcept C104317684 @default.
• W4283381098 hasConcept C126322002 @default.
• W4283381098 hasConcept C143998085 @default.
• W4283381098 hasConcept C150194340 @default.
• W4283381098 hasConcept C167135981 @default.
• W4283381098 hasConcept C185592680 @default.
• W4283381098 hasConcept C187212893 @default.
• W4283381098 hasConcept C190727270 @default.
• W4283381098 hasConcept C2776239401 @default.
• W4283381098 hasConcept C2780007613 @default.
• W4283381098 hasConcept C2780240888 @default.
• W4283381098 hasConcept C2780817109 @default.
• W4283381098 hasConcept C2908647359 @default.
• W4283381098 hasConcept C55493867 @default.
• W4283381098 hasConcept C71924100 @default.
• W4283381098 hasConcept C72563966 @default.
• W4283381098 hasConcept C99454951 @default.
• W4283381098 hasConceptScore W4283381098C104317684 @default.
• W4283381098 hasConceptScore W4283381098C126322002 @default.
• W4283381098 hasConceptScore W4283381098C143998085 @default.
• W4283381098 hasConceptScore W4283381098C150194340 @default.
• W4283381098 hasConceptScore W4283381098C167135981 @default.
• W4283381098 hasConceptScore W4283381098C185592680 @default.
• W4283381098 hasConceptScore W4283381098C187212893 @default.
• W4283381098 hasConceptScore W4283381098C190727270 @default.
• W4283381098 hasConceptScore W4283381098C2776239401 @default.
• W4283381098 hasConceptScore W4283381098C2780007613 @default.
• W4283381098 hasConceptScore W4283381098C2780240888 @default.
• W4283381098 hasConceptScore W4283381098C2780817109 @default.
• W4283381098 hasConceptScore W4283381098C2908647359 @default.
• W4283381098 hasConceptScore W4283381098C55493867 @default.
• W4283381098 hasConceptScore W4283381098C71924100 @default.
• W4283381098 hasConceptScore W4283381098C72563966 @default.
• W4283381098 hasConceptScore W4283381098C99454951 @default.
• W4283381098 hasLocation W42833810981 @default.
• W4283381098 hasLocation W42833810982 @default.
• W4283381098 hasLocation W42833810983 @default.
• W4283381098 hasLocation W42833810984 @default.
• W4283381098 hasOpenAccess W4283381098 @default.
• W4283381098 hasPrimaryLocation W42833810981 @default.
• W4283381098 hasRelatedWork W1972905848 @default.
• W4283381098 hasRelatedWork W1978358623 @default.
• W4283381098 hasRelatedWork W2074796331 @default.
• W4283381098 hasRelatedWork W2117333061 @default.
• W4283381098 hasRelatedWork W2295627690 @default.
• W4283381098 hasRelatedWork W2611734568 @default.
• W4283381098 hasRelatedWork W2996525334 @default.
• W4283381098 hasRelatedWork W3087355768 @default.
• W4283381098 hasRelatedWork W3133007702 @default.
• W4283381098 hasRelatedWork W3198571839 @default.
• W4283381098 hasVolume "6" @default.
• W4283381098 isParatext "false" @default.
• W4283381098 isRetracted "false" @default.
• W4283381098 workType "article" @default.